Ropivacaine (Naropin®) is the pure S (−)-enantiomer of propivacaine, and is a long-acting
amide local anaesthetic agent, eliciting nerve block via reversible inhibition of sodium ion …

Ropivacaine is a long-acting, enantiomerically pure (S-enantiomer) amide local anaesthetic
with a high pK a and low lipid solubility which blocks nerve fibres involved in pain …

Synopsis The enantiomerically pure (S-enantiomer) amide local anaesthetic drug
ropivacaine blocked nerve fibres responsible for transmission of pain (Aδ and fibres) more …

Ropivacaine (Naropin®, AstraZeneca) a new long-acting amide local anaesthetic agent, is a
pure S-enantiomer, with a high pKa and relatively low-lipid solubility. Since its clinical …

Ropivacaine is a long-acting amide local anaesthetic agent and first produced as a pure
enantiomer. It produces effects similar to other local anaesthetics via reversible inhibition of …

Ropivacaine has two advantages over bupivacaine. It provides more differential block when
given epidurally, allowing for a better separation between sensory and motor block. This …

Ropivacaine is a long-acting amide-type local anaesthetic, released for clinical use in 1996.
In comparison with bupivacaine, ropivacaine is equally effective for subcutaneous …

Purpose Ropivacaïne is a new long-acting, injectable local anaesthetic currently undergoing
clinical investigation world wide. It is structurally very similar to bupivacaine, but with less …

Methods Each treatment group consisted of eight healthy men. After a bolus dose of 10 mL
at the L2-L3 interspace, the solution in question was infused at 10 mL/h for 21 hours …

Ropivacaine is a new aminoamide local anaesthetic. Compared with bupivacaine,
ropivacaine possesses a higher threshold for systemic toxicity and a high selectivity for …